Is molecular testing in the guidelines?

Guidelines emphasize identifying the organism and susceptibility. Molecular panels deliver identification and resistance genes far faster; phenotypic susceptibility retains a role.

Should I insist on a culture?

In complicated cases, phenotypic susceptibility is useful. The physician will tell you when it adds something.

Why not just treat empirically?

Because empiric therapy fails often enough — and finding out by getting worse is expensive in every sense.

Where can I read the guidelines?

They are public. Links are below.

What Do the Guidelines Actually Recommend About Testing?

Medically reviewed by our MD Laboratory Director (a role required by CLIA; the director's name is on file in the CMS CLIA database, #45D2048957, and can be verified independently) · Editorial policy

Molecular fluorescence imaging — Auspicious Laboratory, Houston

Guidelines say test the symptomatic — and stop testing the asymptomatic.CLIA #45D2048957 · CAP #8722734 · Same-day results · Walk-ins welcome

Two consistent messages. First: do not screen or treat asymptomatic bacteriuria in most adults (IDSA) — this is the single biggest source of unnecessary antibiotics in urology. Second: in symptomatic and especially recurrent or complicated infection, identify the organism rather than treating blind, because empiric failure is common and increasingly so.

Not sure what you need? Text us and we will set it up.
📱 Text (713) 832-8892 📞 Call (713) 266-0808

3707 Westcenter Dr Suite 100, Houston, TX 77042 · Walk-ins welcome

Test / do not test

Situation	Guideline position
Symptomatic UTI	Identify the organism, particularly if complicated or recurrent
Asymptomatic adult	Do not screen (IDSA)
Pregnancy	Screen and treat (ACOG / IDSA)
Before urologic procedures	Screen, per guideline
Catheterized, asymptomatic	Do not screen or treat
Recurrent UTI	Work up the cause (AUA) rather than repeat the antibiotic

The guidelines are, in effect, telling clinicians to do less testing in one population and better testing in another. Most practices have got that exactly backwards.

We name drugs, never doses. Treatment statements follow IDSA, AUA and ACOG guidance; dose and duration are a physician's decision.

Same day, start to finish. Sample by 1:00 PM → results at 4:30 PM → if treatment is clinically appropriate, a licensed physician in our partner network sees you between 4:30 and 6:00 PM, a few minutes away. That window is reserved for patients tested here, and your slot is held the moment we take your sample — the slot is held, not hunted. On your own, a same-day appointment is nearly impossible; at an urgent care, you wait in the queue. STAT: ~2 hours, sample in by 3:00 PM.

FAQ

Is molecular testing in the guidelines?: Guidelines emphasize identifying the organism and susceptibility. Molecular panels deliver identification and resistance genes far faster; phenotypic susceptibility retains a role.
Should I insist on a culture?: In complicated cases, phenotypic susceptibility is useful. The physician will tell you when it adds something.
Why not just treat empirically?: Because empiric therapy fails often enough — and finding out by getting worse is expensive in every sense.
Where can I read the guidelines?: They are public. Links are below.

Not sure what you need? Text us and we will set it up.
📱 Text (713) 832-8892 📞 Call (713) 266-0808

3707 Westcenter Dr Suite 100, Houston, TX 77042 · Walk-ins welcome

References

Reach us — privately

No name needed to ask a question. Text is the fastest way to reach us.

💬 Text us 📞 Call us ✉️ Email us

Or send your details below — we will reply by text or email during open hours.